![Blaise Lippa](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Blaise Lippa
Technik-/Wissenschafts-/F&E-Leiter bei
MORC HOLD
Profil
Blaise Lippa is currently the Chief Scientific Officer at Morphic Therapeutic, Inc. since 2015 and at Morphic Holding, Inc. since 2022.
Previously, Blaise worked as the Senior Director-Medicinal Chemistry at Cubist Pharmaceuticals LLC.
Blaise holds a doctorate degree from Stanford University and an undergraduate degree from the University of Michigan.
Aktive Positionen von Blaise Lippa
| Unternehmen | Position | Beginn |
|---|---|---|
| MORC HOLD | Technik-/Wissenschafts-/F&E-Leiter | 12.05.2022 |
Morphic Therapeutic, Inc.
 Morphic Therapeutic, Inc. BiotechnologyHealth Technology Researches and develops small molecules to block transmembrane integrin receptors | Technik-/Wissenschafts-/F&E-Leiter | 01.06.2015 |
Ehemalige bekannte Positionen von Blaise Lippa
| Unternehmen | Position | Ende |
|---|---|---|
| CUBIST PHARMACEUTICALS INC | Corporate Officer/Principal | - |
Ausbildung von Blaise Lippa
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
8
Beziehungen ersten Grades
5
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Engages in research, development and commercialization of pharmaceutical products | Health Technology |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Michigan
 University of Michigan Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Morphic Therapeutic, Inc.
Morphic Therapeutic, Inc. BiotechnologyHealth Technology Researches and develops small molecules to block transmembrane integrin receptors | Health Technology |
Morphic Holding, Inc.
 Morphic Holding, Inc. Pharmaceuticals: MajorHealth Technology Develops oral integrin drugs | Health Technology |
